1The Polyposis Registry, St Mark's Hospital, Harrow, London, United Kingdom 2Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, London, United Kingdom 3Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom.
Dis Colon Rectum. 2012 Oct;55(10):1032-7. doi: 10.1097/DCR.0b013e318266b3ad.
Desmoid tumors associated with familial adenomatous polyposis show variable behavior; about 10% grow relentlessly, resulting in severe morbidity or mortality. Investigations that could identify the minority of desmoid tumors that behave aggressively would allow these tumors to be treated early and spare the majority of patients who have more benign disease from unnecessary intervention.
The aim of this study was to investigate whether imaging the tumor metabolic-vascular phenotype by modern methods predicts growth.
This is a prospective case series study.
The study was conducted at a tertiary center specializing in familial adenomatous polyposis and desmoid disease.
Nine patients with familial adenomatous polyposis (4 male, mean age 39 years) with desmoid tumor underwent 18F-FDG-PET and dynamic contrast-enhanced MRI. Standard MRI was repeated a year later to assess tumor growth.
The primary outcome measured was the correlation between 18F-FDG-PET and dynamic contrast-enhanced MRI parameters and subsequent desmoid growth.
Failed intravenous access precluded dynamic contrast-enhanced MRI in 1 female patient. Thirteen desmoid tumors (4 intra-abdominal, 2 extra-abdominal, 7 abdominal wall; mean area, 68 cm) were analyzed in the remaining 8 patients. Two patients died before follow-up MRI. Five tumors decreased in size, 3 increased in size, and 3 remained stable after a year. Significant correlation (Spearman rank correlation, significance at 5%) existed between maximum standardized uptake value and k(ep) (r = -0.56, p = 0.04), but not with other vascular parameters (K(trans) (r = -0.47, p = 0.09); v(e) (r = -0.11, p = 0.72); integrated area under the gadolinium-time curve at 60 seconds (r = -0.47, p = 0.10)). There was no significant difference in the maximum standardized uptake value or dynamic contrast-enhanced MRI parameters (K(trans), v(e), k(ep), integrated area under the gadolinium-time curve at 60 seconds) between the tumors that grew or decreased in size or between the tumor sites. However, vascular metabolic ratio (maximum standardized uptake value/K(trans)) was significantly different for tumor site (p = 0.001) and size (p = 0.001, 1-way ANOVA).
This investigation is limited because of its exploratory nature and small patient numbers.
Although not predictive for tumor behavior, some correlations existed between dynamic contrast-enhanced MRI and 18F-FDG-PET parameters. Vascular metabolic ratio may provide further information on tumor behavior; however, this needs to be evaluated with further larger studies.
家族性腺瘤性息肉病相关的硬纤维瘤表现出不同的行为;约 10%的硬纤维瘤持续生长,导致严重的发病率或死亡率。能够识别具有侵袭性的少数硬纤维瘤的研究将允许早期治疗这些肿瘤,并使大多数患有良性疾病的患者免受不必要的干预。
本研究旨在探讨通过现代方法对肿瘤代谢-血管表型进行成像是否可以预测肿瘤的生长。
这是一项前瞻性病例系列研究。
该研究在一家专门从事家族性腺瘤性息肉病和硬纤维瘤疾病的三级中心进行。
9 名家族性腺瘤性息肉病患者(4 名男性,平均年龄 39 岁)患有硬纤维瘤,接受了 18F-FDG-PET 和动态对比增强 MRI 检查。标准 MRI 于一年后重复以评估肿瘤生长情况。
主要测量的结果是 18F-FDG-PET 和动态对比增强 MRI 参数与随后的硬纤维瘤生长之间的相关性。
1 名女性患者因静脉内通路失败而无法进行动态对比增强 MRI。在其余 8 名患者中分析了 13 个硬纤维瘤(4 个腹腔内,2 个腹腔外,7 个腹壁;平均面积 68cm)。2 名患者在随访 MRI 前死亡。一年后,有 5 个肿瘤缩小,3 个肿瘤增大,3 个肿瘤稳定。最大标准化摄取值与 k(ep)之间存在显著相关性(Spearman 秩相关,5%的显著性水平)(r=-0.56,p=0.04),但与其他血管参数(K(trans)(r=-0.47,p=0.09);v(e)(r=-0.11,p=0.72);60 秒时钆时间曲线下的积分面积(r=-0.47,p=0.10))无显著相关性。肿瘤大小增大或减小的肿瘤之间,或肿瘤部位之间,最大标准化摄取值或动态对比增强 MRI 参数(K(trans)、v(e)、k(ep)、60 秒时钆时间曲线下的积分面积)均无显著差异。然而,血管代谢比率(最大标准化摄取值/K(trans))在肿瘤部位(p=0.001)和大小(p=0.001,1 路 ANOVA)方面有显著差异。
由于其探索性性质和患者数量较少,本研究受到限制。
尽管对肿瘤行为没有预测作用,但动态对比增强 MRI 和 18F-FDG-PET 参数之间存在一些相关性。血管代谢比率可能提供有关肿瘤行为的进一步信息;然而,这需要进一步的大型研究来评估。